Randomized Clinical Trial on the Long-Term Efficacy and Safety of Lumasiran in Patients With Primary Hyperoxaluria Type 1
Sally A. Hulton(Birmingham Children's Hospital), John C. Lieske(Mayo Clinic), Kristin Meliambro(Icahn School of Medicine at Mount Sinai), David J. Sas(Mayo Clinic), Michael J. Koren(Jacksonville Center for Clinical Research), Hadas Shasha‐Lavsky(Université Claude Bernard Lyon 1), John M. Gansner(Brigham and Women's Hospital), Wesley Hayes(Great Ormond Street Hospital), Anne‐Laure Sellier‐Leclerc(Hôpital Femme Mère Enfant), Eva Šimková(Université Claude Bernard Lyon 1), Jeffrey M. Saland(Université Claude Bernard Lyon 1), Yaacov Frishberg(Shaare Zedek Medical Center), Sander F. Garrelfs(Emma Kinderziekenhuis), Martin Coenen(University Hospital Bonn), Bahru Habtemariam(Center for Drug Evaluation and Research), Daniella Magen(Université Claude Bernard Lyon 1), Taylor Ngo(Boehringer Ingelheim (Germany)), Shabbir H. Moochhala(Université Claude Bernard Lyon 1), Tracy L. McGregor(Université Claude Bernard Lyon 1), Marianne T. Sweetser(Alnylam Pharmaceuticals (United States)), J. Scott Overcash(Precision Research Institute), Jaap W. Groothoff(University of Amsterdam)
Cited by 32
Related Papers
Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis
|New England Journal of Medicine|2018|2.9k
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
|New England Journal of Medicine|2015|1.5k
FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome
|The Oncologist|2018|880
Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials
|The Lancet|2019|785
A 52-Week Placebo-Controlled Trial of Evolocumab in Hyperlipidemia
|New England Journal of Medicine|2014|712